Mission
Our Vision
Our Values

About Us

Guangzhou Gineo Biotechnology Co., Ltd.

Jennio has a laboratory area of over 2,000 square meters, including GMP-standard resources of over 1,000 cell lines and nearly 10,000 target resources covering various pathways. With an SPF-level efficacy research platform, we can provide over 70 different animal disease models for various clinical phenotypes and indications, as well as 300+ CDX/PDX models. Focusing on the innovative drug development needs around new targets and mechanisms, Jennio always pays attention to the industry's lack of practical disease models, providing users with customized disease models and efficacy solutions that meet clinical phenotypes and pathogenesis.

Serving over 50 large pharmaceutical companies
50

Serving over 50 large pharmaceutical companies

Over 50000 mouse models delivered within 7 years
50000

Delivered 50000+ mouse models within 7 years

Collection of 1000+cell lines
1000

Collection of 1000+cell lines

MORE
视频标题

Our Services

In vitro drug efficacy research In vivo drug efficacy research Non-GLP pharmacology and toxicology study Specialized drug efficacy research platform

News

New drugs may prevent cancer metastasis by promoting cancer cells to enter dormancy

New drugs may prevent cancer metastasis by promoting cancer cells to enter dormancy

Metastasis, the leading cause of cancer-related death, arises primarily from the "seed" of secondary organs by disseminated tumor cells (DTCs, DTCs) that persist in the body before triggering symptomatic overt metastases Dormant for years or decades

time：

2020/05/26

Scientists discover novel link between CRISPR gene-editing technology and mutated cancer cells

Scientists discover novel link between CRISPR gene-editing technology and mutated cancer cells

p53, a special protein that protects cells from DNA damage, is activated during gene editing using CRISPR technology; inactivating p53 mutations are the most abundant genetic alterations in cancer, and cells carrying mutated p53 often have Certain survival advantage, which may eventually lead to cancer

time：

2020/05/26

How to deal with the unreliability of early data in new drug development

How to deal with the unreliability of early data in new drug development

Several events that happened last week are worthy of our comprehensive analysis. Although the mechanism of the PCSK9 antibody Repatha is highly reliable, it did not achieve the expected efficacy in the Fourier trial of 27,000 people; the hormone drug, recombinant relaxin Serelaxin, failed in a larger phase III clinical trial after seeing a survival advantage in a phase III clinical trial

time：

2020/05/09

NASH clinical trials recruit patients slowly, what's the situation?

NASH clinical trials recruit patients slowly, what's the situation?

French biotech company Genfit announced today that its Phase 3 RESOVLE-IT trial of its NASH drug elafibranor is slow to enroll patients. The recruitment speed of early patients is acceptable, but the enrollment progress of advanced patients is lower than expected. The trial is expected to be delayed by 4-6 months and will take the first quarter of next year to enroll 1,000 patients. This is another NASH leading product clinical trial progress blocked following Intercept's OCA phase III clinical trial. NASH is considered the next major drug market with a huge patient population. Moreover, NASH has serious consequences and will become a liver disease.

time：

2020/05/11

Who is the real disease: the tumor or the tumor microenvironment?

Who is the real disease: the tumor or the tumor microenvironment?

Ever since Director Qi cut himself off from the people, I wondered why such an aspiring young man and anti-drug hero became corrupt? With my little political awareness, I definitely can't understand this complicated process, but it reminds me of the tumor problem.

time：

2020/05/11

10 times higher resolution! AI-assisted microscope upgrade can generate high-definition 3D images

10 times higher resolution! AI-assisted microscope upgrade can generate high-definition 3D images

In the 1950s, artificial intelligence pioneer Marvin Minsky proposed confocal microscopy. Compared with traditional microscopes, this new technology that can obtain serial slices and present the three-dimensional appearance of objects has quickly gained favor and entered biological laboratories all over the world

time：

2021/12/02

More

Our Team

Our Team

Friendly Links

英语翻译-----这个提示重复怎么也添加不上
思诚资源
变频器厂家
n厂手表
宣传片拍摄
残疾人升降平台
美国试管婴儿费用
自学日语
香港基因检测
深信服
钢结构夹层楼板
Assignment代写
胶质瘤
黑金刚电容
快赴康海外医疗
聚酰亚胺pi镀铜膜厂家
泡酒配方大全
FITC荧光标记抗体
自学土木
光电显微镜
英语翻译
净化板
公司注册
真空吸塑机
职校招生
蜜雪冰城
水质分析仪